← Human Trials & Peer-Reviewed Studies
Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome
Plain-language guide to NCT06635629: phase 2 randomized trial of Desmopressin, 140 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT06635629
- Phase
- phase 2
- Status
- recruiting participants
- Start
- 2024-12-12
- Completion (planned or actual)
- 2028-10-01
- Participants
- 140 (estimated)
- Design
- randomized, single-blind, diagnostic
- Conditions studied
- Cushing Syndrome
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
In this phase 2 trial, researchers set out to test Desmopressin.
ACTH stimulates the production of a hormone called cortisol.
It had four arms (groups): one (other), one (active comparator), one (active comparator) and one (active comparator).
The registry classes the interventions as drug.
Who Took Part
The registry lists 140 planned participants were the target.
It was open to people of any sex aged from 18 years up to 70 years.
Healthy volunteers could join, not only people with the condition.
Examples of who could join: Aged 18-70 years. Agreement to adhere to Lifestyle Considerations throughout the study.
The full record lists 9 inclusion and 26 exclusion criteria; among the exclusions: inability to comply with all study procedures and visits; inability of subject to understand or to sign a written informed consent document; known allergy/hypersensitivity to desmopressin.
How the Study Was Run
The set-up was randomized, sequential and single-blind.
Random assignment meant chance, not the researchers, decided who got Desmopressin and who got the comparison, which limits bias.
Only one side, usually the participants, was kept unaware of whether Desmopressin was given.
Those kept unaware of assignments: participant.
It started in 2024-12-12 with completion listed for 2028-10-01.
It ran at 1 site in United States.
Its stated primary purpose is diagnostic.
What Was Measured
Researchers chose this as the main measure: ACTH and cortisol responses (time frame: -5, 0, 15, 30, 45 and 60 minutes).
It also tracked 1 secondary outcome, for example Diagnostic accuracy, specificity, sensitivity of cortisol and ACTH measurements in response to desmopressin.
What This Means in Plain Language
Put simply, this is a phase 2, randomized trial of Desmopressin in 140 people.
It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the Desmopressin compound page, all human trials.
Our Notes on the Compound
Desmopressin: A synthetic vasopressin analog (DDAVP) used for bedwetting, diabetes insipidus and some bleeding disorders.
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.